

: Mrs. REKHA

INDIA OP AGREEMENT

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

Address : DELHI

Plan

Age: 35 Y

Sex: F

UHID:SCHI.0000017944

OP Number: SCHIOPV25908

Bill No: SCHI-OCR-9350

Sno	Serive Type/ServiceName	
1	ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK	Department
	GAMMA GLUTAMYL TRANFERASE (GGT)	- FEMALE - 2D ECHO - PAN INDIA - FY2324
2	2 D ECHO Jender	
	LIVER FUNCTION TEST (LFT)	
	GLUCOSE, FASTING	
5	HEMOGRAM + PERIPHERAL SMEAR	
6	GYNAECOLOGY CONSULTATION,	
	DIET CONSULTATION	
. 8	COMPLETE URINE EXAMINATION	
9	URINE GLUCOSE(POST PRANDIAL)	
	PERIPHERAL-SMEAR	
11	ECG V	
12	LBC PAP TEST- PAPSURE	
13	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
14	DENTAL CONSULTATION V	
15	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	
16	URINE GLUCOSE(FASTING)	
17	HbAIc, GLYCATED HEMOGLOBIN	
18	X-RAY CHEST PA	
19	ENT CONSULTATION	
20	FITNESS BY GENERAL PHYSICIAN	
21	BLOOD GROUP ABO AND RH FACTOR	
	LIPID PROFILE	
23	BODY MASS INDEX (BMI)	
24	OPTHAL BY GENERAL PHYSICIAN Ports	
25	ULTRASOUND - WHOLE ABDOMEN	
	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	

Height: LS U Pulse: 86 Spor agis

SITURDE विसाध स्ट्रिकार स्ट्रिकार INCOME TAX DEPARTMENT GOVT. OF INDIA


VIJAY PAL

12/06/1988
Permanent Account Number BWKPR5769J

Signature

Client Name ARCOFEMI HEALTHCARE LIMITED

Patient Name REKHA





			-	MDC/F
NAME:	REKHA	AGE/SEX	35	YRS/ F
UHID:	17944			
REF BY :	APOLLO SPECTRA	DATE:-	10.02	2.2024

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No mass lesion is seen. Ureter is not dilated.

A 3.5 mm echogenic focus seen in the mid pole of the right kidney suggestive of calculus. Right renal calculus.

A 3 mm echogenic focus seen in the mid pole of the left kidney suggestive of calculus. left renal calculus.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Uterus is antiverted and normal in size. It measures 6.4 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 2.4 mm

Both ovaries are normal in size ,shape and echotexture.

Right ovary: 1.8 x 2.4 cm Left ovary: 2.0 x 1.9 cm

No obvious adenexal mass is seen. No free fluid seen.

IMPRESSION: BILATERAL SILENT RENAL CALCULI.

Please correlate clinically and with lab. Investigations.

DR. PRADEEP DUTTA Consultant Radiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

CERTIFICATE OF MEDICAL FITNESS

This is to certify that I have conducted the clinical examination

			Ti
•	Medically Fit	-	
٠	Fit with restrictions/recommendations		1
	Though following restrictions have been revealed, in my opinion, these and not impediments to the job.	re	
	1		
	2		
	3		
	However the employee should follow the advice/medication that has been communicated to him/her.		
	Review after		
	Currently Unfit.		+

Medical Officer
The Apollo Clinic, Uppal

This certificate is not meant for medico-legal purposes

PREVENTIVE HEALTH CARE SUMMARY

NAME:- Relation	UHID No: 78
AGE/GENDER:- 35.	
PANEL: 14	RECEIPT No : -
to colem	EXAMINED ON : - 0
Chief Complaints:	Hollenal Cala
Past History:	
DM : Nil Hypertension : Nil CAD : Nil	CVA : NIT Cancer : NIT Other : NIL
Personal History:	·
Alcohol : Mil Smoking : Nil	Activity : Active Allergies : Nil
Family History: DM HT General Physical Examination:	
Height Sy: cms Weight 53.5: Kgs Rest of examination was within normal lim	Pulse 86/199 bpm BP 110/80 mmHg-
Systemic Examination:	
CVS Respiratory system : Normal Abdominal system : Normal CNS : Normal Others : Normal	

PREVENTIVE HEALTH CARE SUMMARY

NAME :-	
ACE	UHID No:
AGE :- SEX:	RECEIPT No:-
PANEL:	EXAMINED ON:-

Investigations:

• All the reports of tests and investigations are attached herewith

Recommendation:

· Monty offlied.

Gap Absolute women 102 x1-2 moth
My vite Dz 60 k once a week

400 consullets

Alean

Dr. Navneet Kaur Consultant Physician LMP-19.1.24. PILI - Syn / m

PH - hidney shones ? Buchache / slip dise.

Rekha 10.2.24 354/F

Specialists in Surgery

M- James - 4 W+ DM

brean+

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



DIGITAL X-RAY REPORT

NAME: REKHA	DATE: 10.02.2024
UHID NO: 17944	AGE: 35YRS/ SEX: F

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA

Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com





: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received Reported : 10/Feb/2024 10:32AM : 10/Feb/2024 05:18PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240033690

Page 1 of 13







: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received Reported : 10/Feb/2024 10:32AM : 10/Feb/2024 05:18PM

Status : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	10.2	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	34.80	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.74	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	73.4	fL	83-101	Calculated
MCH	21.4	pg	27-32	Calculated
MCHC	29.2	g/dL	31.5-34.5	Calculated
R.D.W	16	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	7,700	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	56.5	%	40-80	Electrical Impedance
LYMPHOCYTES	33.9	%	20-40	Electrical Impedance
EOSINOPHILS	3	%	1-6	Electrical Impedance
MONOCYTES	6.3	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT		·		
NEUTROPHILS	4350.5	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2610.3	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	231	Cells/cu.mm	20-500	Calculated
MONOCYTES	485.1	Cells/cu.mm	200-1000	Calculated
BASOPHILS	23.1	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	305000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	35	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH FEW MICROCYTIC HYPOCHROMIC CELLS.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Dr. SHWETA GUPTA MBBS,MD (Pathology)

Consultant Pathology SIN No:BED240033690



Page 2 of 13





: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received

: 10/Feb/2024 10:32AM : 10/Feb/2024 05:18PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240033690

Page 3 of 13





Patient Name : Mrs.REKHA Age/Gender : 35 Y 7 M 28 D/F

UHID/MR No : SCHI.0000017944 Visit ID : SCHIOPV25908

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : ATGsewyh Collected : 10/Feb/2024 09:58AM
Received : 10/Feb/2024 10:32AM
Reported : 10/Feb/2024 11:52AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA						
BLOOD GROUP TYPE	0			Forward & Reverse Grouping with Slide/Tube Aggluti		
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination		

Page 4 of 13









: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 12:41PM

Received

: 10/Feb/2024 01:34PM

Reported

: 10/Feb/2024 04:49PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	93	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	100	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 13



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:PLP1417729



Ref Doctor



Patient Name : Mrs.REKHA

Age/Gender : 35 Y 7 M 28 D/F

UHID/MR No : SCHI.0000017944

: Dr.SELF

Visit ID : SCHIOPV25908

Emp/Auth/TPA ID : ATGsewyh Collected : 10/Feb/2024 09:58AM

Received : 10/Feb/2024 12:38PM

Reported : 10/Feb/2024 01:32PM

Status : Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
HBA1C (GLYCATED HEMOGLOBIN), WHOLE BLOOD EDTA					
HBA1C, GLYCATED HEMOGLOBIN	5.4	%		HPLC	
ESTIMATED AVERAGE GLUCOSE (eAG)	108	mg/dL		Calculated	

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240014881

Page 6 of 13





Patient Name : Mrs.REKHA

Age/Gender : 35 Y 7 M 28 D/F

UHID/MR No : SCHI.0000017944

Visit ID : SCHIOPV25908

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : ATGsewyh Collected : 10/Feb/2024 09:58AM

Received : 10/Feb/2024 10:31AM

Reported : 10/Feb/2024 11:39AM Status : Final Report

Status : Final Report
Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	146	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	106	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	47	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	99	mg/dL	<130	Calculated
LDL CHOLESTEROL	77.8	mg/dL	<100	Calculated
VLDL CHOLESTEROL	21.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.11		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

Reference interval as per reational endesteror Education Frogram (NeEr) Future Frederick Failer in Report.					
	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 13



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:SE04625273





Patient Name : Mrs.REKHA

Age/Gender : 35 Y 7 M 28 D/F

UHID/MR No : SCHI.0000017944

Visit ID : SCHIOPV25908

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : ATGsewyh Collected : 10/Feb/2024 09:58AM

Received : 10/Feb/2024 10:31AM

Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method				
LIVER FUNCTION TEST (LFT) , SERUM	IVER FUNCTION TEST (LFT) , SERUM							
BILIRUBIN, TOTAL	0.60	mg/dL	0.20-1.20	DIAZO METHOD				
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.0-0.3	Calculated				
BILIRUBIN (INDIRECT)	0.40	mg/dL	0.0-1.1	Dual Wavelength				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	19	U/L	<35	Visible with P-5-P				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	28.0	U/L	14-36	UV with P-5-P				
ALKALINE PHOSPHATASE	82.00	U/L	38-126	p-nitrophenyl phosphate				
PROTEIN, TOTAL	7.80	g/dL	6.3-8.2	Biuret				
ALBUMIN	3.80	g/dL	3.5 - 5	Bromocresol Green				
GLOBULIN	4.00	g/dL	2.0-3.5	Calculated				
A/G RATIO	0.95		0.9-2.0	Calculated				

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 13



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:SE04625273





: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received

: 10/Feb/2024 10:31AM

Reported Status : 10/Feb/2024 11:39AM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM							
CREATININE	0.60	mg/dL	0.5-1.04	Creatinine amidohydrolase			
UREA	16.00	mg/dL	15-36	Urease			
BLOOD UREA NITROGEN	7.5	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	4.10	mg/dL	2.5-6.2	Uricase			
CALCIUM	9.40	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	4.20	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	135	mmol/L	135-145	Direct ISE			
POTASSIUM	4.2	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	101	mmol/L	98 - 107	Direct ISE			

Page 9 of 13









: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received

: 10/Feb/2024 10:31AM

Reported

Status

: 10/Feb/2024 11:14AM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	13.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 10 of 13









Patient Name : Mrs.REKHA

Age/Gender : 35 Y 7 M 28 D/F

UHID/MR No : SCHI.0000017944

Visit ID : SCHIOPV25908 Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : ATGsewyh Collected : 10/Feb/2024 09:58AM

Received : 10/Feb/2024 10:31AM

Reported : 10/Feb/2024 05:00PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	1.2	ng/mL	0.67-1.81	ELFA		
THYROXINE (T4, TOTAL)	9.62	μg/dL	4.66-9.32	ELFA		
THYROID STIMULATING HORMONE (TSH)	1.570	μIU/mL	0.25-5.0	ELFA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:SPL24022191





: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received

: 10/Feb/2024 11:48AM

Reported Status : 10/Feb/2024 04:55PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
COMPLETE URINE EXAMINATION (CUE) , URINE							
PHYSICAL EXAMINATION							
COLOUR	PALE YELLOW		PALE YELLOW	Visual			
TRANSPARENCY	CLEAR		CLEAR	Visual			
рH	6.0		5-7.5	Bromothymol Blue			
SP. GRAVITY	1.015		1.002-1.030	Dipstick			
BIOCHEMICAL EXAMINATION							
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR			
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD			
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING			
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE			
UROBILINOGEN	NORMAL		NORMAL	EHRLICH			
BLOOD	NEGATIVE		NEGATIVE	Dipstick			
NITRITE	NEGATIVE		NEGATIVE	Dipstick			
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS			
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	(
PUS CELLS	2-3	/hpf	0-5	Microscopy			
EPITHELIAL CELLS	3-5	/hpf	<10	MICROSCOPY			
RBC	ABSENT	/hpf	0-2	MICROSCOPY			
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY			
CRYSTALS	ABSENT		ABSENT	MICROSCOPY			

Page 12 of 13



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:UR2279651





: Mrs.REKHA

Age/Gender

: 35 Y 7 M 28 D/F

UHID/MR No

: SCHI.0000017944

Visit ID Ref Doctor : SCHIOPV25908

Emp/Auth/TPA ID

: Dr.SELF : ATGsewyh Collected

: 10/Feb/2024 09:58AM

Received

: 10/Feb/2024 11:50AM

Reported Status : 10/Feb/2024 04:57PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick
				•

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick

*** End Of Report ***

Result/s to Follow:

LBC PAP TEST (PAPSURE)

Page 13 of 13

